Chronic Kidney Disease
Chronic Kidney Disease in Primary Care: Small Changes That Make a Big Difference
CKD is common, but progression is not inevitable.
William Burlace21 days ago · 5 min read
Evidence
Browse all clinical evidence, news, and expert commentary
Chronic Kidney Disease
Finerenone may slow kidney decline in glomerular disease
A prespecified exploratory analysis of the FIND-CKD trial reports slower eGFR decline with finerenone in chronic kidney disease due to glomerular diseases.
Medicine Central Editorial Team29 days ago · 5 min read
Chronic Kidney Disease
Finerenone linked to fewer sudden deaths across the CKM spectrum
Sudden death is the single leading cardiovascular cause of death in cardio-kidney-metabolic syndrome, a pooled analysis of nearly 19,000 trial participants finds. Here is what the FINE-HEART data show, and what they mean for primary care.
2 months ago · 2 min read
Type 2 Diabetes
NG28 NICE GUIDELINES: The Flozin-First Era, and 810,000 More GLP-1 Patients
The February 2026 update to NG28 ends that era. Most newly diagnosed patients will now be offered an SGLT-2 inhibitor alongside metformin from the outset.
3 months ago · 3 min read
Chronic Kidney Disease
SGLT2 trial watch
When a patient stops a medication, the assumption is usually that the benefits stop too. The EMPA-KIDNEY post-trial follow-up, published in NEJM, checked if this is true for SGLT2 inhibitors in CKD.
5 months ago · 2 min read
Chronic Kidney Disease
Falling through the GAAP: when patients diagnose themselves
One in 10 patients surveyed by Kidney Care UK found out they had CKD by seeing it recorded in the NHS App. Almost 40% had no opportunity to discuss the diagnosis with a healthcare professional.
5 months ago · 2 min read
Chronic Kidney Disease
The Kidney Failure Risk Equation: who should we refer?
The kidney failure risk equation is now in NICE guidance. A new BJGP study from Greater Manchester found that, for most patients, the risk of death is much higher than the risk of needing dialysis.
5 months ago · 2 min read
Chronic Kidney Disease
SGLT2i vs GLP-1 RA: which one offers more kidney protection?
Both SGLT2 inhibitors and GLP-1 receptor agonists protect the kidneys in type 2 diabetes. A large new JAMA study is the closest we have to a head-to-head answer — and the results are not straightforward.
6 months ago · 2 min read
Page 1